The genes controlling long-term weight changes are largely unknown. The beta1 (b1)-adrenoceptor gene contains two nonsynonomous single nucleotide polymorphisms (SNPs), Ser49Gly and Gly389Arg, that both are functional in human cell lines. DESIGN: We investigated the influence of these two SNPs on short-and long-term changes in body mass index (BMI) in a population-based cohort of 761 women who were examined during pregnancy in 1984-1985 and 15 y thereafter. RESULTS: At entry, no genotype effect on BMI was found. After 15 y, the BMI of women carrying the Gly49-genotype (25.370.3 kg/m 2 ) was higher (Po0.005) than that of Ser49-women (24.470.2 kg/m 2 ). Also, the BMI-increase over 15 y was higher (P ¼ 0.018) in Gly49-women (3.370.2 kg/m 2 ) than in Ser49-women (2.870.1 kg/m 2 ). The odds ratio for being overweight after 15 y having the Gly49-genotype was 1.6 (confidence interval 1.1-2.3, P ¼ 0.01). No effect of SNP 389 alone on BMI was found but there was a genotype-genotype interaction. Those carrying the Gly49-Gly389 combination increased their BMI about 0.7 kg/m 2 more than other combinations (P ¼ 0.025). No genotype effect on BMI changes during pregnancy for either SNP was found. CONCLUSION: Polymorphism of the b1-adrenoceptor gene influences long-term weight gain and the incidence of adult-onset overweight in women.
Introduction
In view of the alarming increase in the incidence of obesity in many countries and its consequence for development of type 2 diabetes, it is essential to find the genetic factors that contribute to changes in body weight over time. The genes that are important for body weight changes in man are largely unknown. In relatively few cases of obesity occurring in its monogenic form, there is a rapid increase of body weight already at the early stages of life. 1 For weight gain in the general population, studies showing association between genetic variance and spontaneous weight gain over time are limited. Genes that have been studied in this context include those for the leptin receptor, 2 the alpha2B-adrenergic receptor, 3 the peroxisome proliferator receptor gamma-2, 4,5 the beta2-6,7 and beta3- 8, 9 adrenergic receptors and the reninangiotensin system.
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Beta1 (b1)-adrenoceptor signaling transduction could be important for long time changes in body weight because this receptor plays a central role for metabolism in various organs including adipose tissue and muscle. The b1-adrenoceptor gene is highly polymorphic and two nonsynonomous single nucleotide polymorphisms (SNPs), A231G and G1251C, each followed by amino-acid changes of the protein, Ser49Gly and Gly389Arg, respectively, have been described. 11 Results from recombinant cell lines also suggest that the Ser49Gly polymorphism affects agonist promoted downregulation 12 whereas the Gly389Arg variation influences receptor-Gs interaction with functional consequences for signal transduction. 13 In the present study, we investigated the role of the functional Ser49Gly and Gly389Arg polymorphisms for short-and long-term changes in body weight in a large sample of women. For this purpose, we utilized a populationbased cohort of women who were recruited at the early stage of pregnancy during 1984-1985 from a maternity unit. These women were followed during pregnancy and reinvestigated 15 y thereafter. 14 
Methods
The study comprised 761 women who were recruited in 1984-1985 to take part in a longitudinal study of women's weight development during pregnancy and at 15 y of followup. 14 The women were invited by their midwives to take part in the study when they routinely visited the maternity clinic 2.5 months after delivery. The sample represents a mixed metropolitan population from both the inner city area and suburb districts with a distribution in social groups that can be assumed to correspond to the population in the Stockholm area. All women were apparently healthy. Data were collected for age, parity, length and body weight. The women were weighed and their length measured by the staff at the maternity clinics on the same scale without shoes and in light indoor clothing to the nearest 0.1 kg and 0.02 m, respectively. The scales were calibrated in each maternity clinic. The women self-reported their body weight and heights before conception at the first visit to the maternity clinic, usually between gestation weeks 8 and 12. The prepregnancy body mass index (BMI) was calculated from self-reported weight and height. There was an excellent correlation between prepregnancy self-reported weight and the weight measured in gestation weeks 8-12 (r ¼ 0.94, Po0.0001, slope not different from 1.0). Data on weightchange during pregnancy and birth-weight of the child were recorded (data missing in 57 subjects) At 15 y of follow-up, which took place at the Clinical Research Unit at Huddinge University Hospital, participants completed a questionnaire containing questions about physical activity at work and leisure time to be subdivided into three groups; 1 ¼ no physical activity either at work or during leisure time, 2 ¼ moderate physical activity either at work/leisure time or both and 3 ¼ high physical activity at work/leisure time or both. Again data were collected on parity, height and weight, which were recorded, as described above. Blood was drawn for genetic analyses.
Genotype determination of the b1-adrenoceptor polymorphisms was accomplished using restriction fragment length polymorphism. For the Ser49Gly-polymorphism, the primers used were 5 0 -ATGGGCGCGGGGGTGCTCGTC-3 0 (sense) and 5 0 -GAAACGGCGCTCGCAGCTGTCG-3 0 (antisense). Cleavage of the PCR-product by EcoO1091 produced fragments of 528 and 266 bp (Ser49-homozygotes), 528, 383, 266 and 145 bp (Ser49Gly-heterozygotes) or 383, 266 and 145 bp (Gly49-homozygotes). The primers used for the Gly389Arg-polymorphism were 5 0 -CTCTGCTGGCTGCCCTT CTTC-3 0 (sense) and 5 0 -GGGCTTCGAGTTCACCTGCTATC-3 -value of 0.016. The frequency of subjects homozygous for the Gly49-and Gly389-alleles was only 3 and 6 %, respectively. Therefore, in subsequent analyses, subjects carrying the Gly49-allele (n ¼ 200) or the Gly389-allele (n ¼ 356) in its homo-or heterozygous form (termed Gly49 and Gly389) were investigated together in comparison with subjects homozygous for the Ser49-and Arg389-alleles (termed Ser49, n ¼ 561, and Arg389, n ¼ 404), respectively. There was no difference in age between genotypes, 29.270.3 (Gly49) vs 29.270.2 (Ser49), P ¼ 0.83, 29.170.2 (Gly389) vs 29.170.3 (Arg389), P ¼ 0.62. With respect to physical activity, data were available from 708 subjects; 16 women belonged to category 1, 682 to category 2 and 10 to category 3. No difference in physical activity between genotypes Gly49/Ser49 or Gly389/Arg389 was found (P ¼ 0.27 and 0.43, respectively, by w 2 analysis).
Finally, no difference in parity was found for either genotype, Gly49/Ser49 (P ¼ 0.33) or Gly389/Arg389 (P ¼ 0.18 by w 2 analysis).
As shown in Table 2 , at entry, there was no difference in BMI of the b1-49-polymorphism. In contrast, both the increase in BMI during 15 y, and the BMI at 15 y follow-up, was higher in Gly49 subjects as compared to Ser49 subjects. The corresponding weight increase over 15 y was 9.070.3 kg (Gly49) and 7.870.3 kg (Ser49), P ¼ 0.045. These differences persisted when values were corrected for age, parity or exercise levels. However, there was no effect of the b1-389-polymorphism on either of the BMI parameters. Moreover, neither of the b1-gene polymorphisms showed any impact on BMI change during pregnancy. The latter was also true when BMI changes during pregnancy were corrected for birth-weight of the child. At entry, the distribution of both genotypes was similar in lean, overweight and obese subjects. However, with respect to BMI after 15 y of follow-up, the frequency of the Gly49-genotype was increased in overweight subjects but not altered among the obese, whereas no difference in distribution between weight categories was found regarding the b1-389-polymorphism, see Table 3 . By logistic regression analysis, the risk of becoming overweight having the Gly49-genotype was calculated. The odds ratio was found to be 1.6 (confidence interval 1.1-2.3, P ¼ 0.01).
We also investigated the interaction between the two polymorphisms on BMI progress over 15 y. As shown in Figure 1 , the subgroup of women with the Gly49-genotype also having the Gly389-genotype had a larger increase in BMI Finally, haplotype analysis revealed the existence of three haplotypes, Ser49-Arg389 (65%), Ser49-Gly389 (21%) and Gly49-Arg389 (14%). However, no difference between the haplotypes on BMI increase during 15 y was found (P ¼ 0.18 by ANOVA).
Discussion
In the present study, the primary finding on the b1-adrenoceptor polymorphism was a larger long-term increase in BMI over 15 y in women carrying the Gly49-genotype as compared with Ser49-women. The frequency of Gly49-women being classified as overweight after 15 y of followup was 50% higher than in women with the Ser49-genotype. Furthermore, the Gly389-genotype was found to interact with the Gly49-genotype to define a Gly49/Gly389-subgroup as being the most sensitive one to high weight gain among the variations in the b1-adrenoceptor gene.
When studying complex traits such as weight development over time, data need to be analyzed carefully bearing in Values were compared by w 2 analysis using the actual number of subjects in each weight category.
Ser49-Gly/Arg389
Gly49-Arg389 Gly49-Gly389 mind that the associations found may be casual. However, since our study is population based, it is unlikely that selection bias influenced the results. It remains, though, to be established whether the same kind of findings are observed in men or in other populations such as nonScandinavian women.
In this study, no data on metabolic parameters or incidence of diabetes mellitus were available. Nevertheless, it is well known that weight gain over time is associated with an increased risk of both insulin resistance [17] [18] [19] and diabetes mellitus. [20] [21] [22] For instance, in women followed 28-48 y after pregnancy, the relative BMI increase of subjects developing diabetes mellitus was about 2 kg/m 2 higher than in women remaining nondiabetic. 22 Consequently, a moderate weight gain over a long period of time, as the present finding of b1-adrenoceptor gene polymorphism associated BMI increase (about 0.5-1 kg/m 2 ), may be of importance also for metabolic risk factor development.
It is evident that the investigated gene polymorphisms, although being important for long-term weight changes, have little or no effect on short time changes in BMI. Although pregnancy is usually associated with a marked increase in body weight, no genotype effect on pregnancyinduced changes in BMI was found, possibly because such short-term changes is influenced primarily by environmental and behavioral, rather than genetic, factors.
The b1-adrenoceptor is constitutively expressed in various tissues where it functions to mediate catecholamine-induced effects. In congestive heart failure, the Gly49-variant of the b1-adrenoceptor gene was shown to be associated with a decreased mortality risk. 23 This finding may be explained by an increased in vitro desensitization, followed by low levels of cAMP of the Gly49-variant of the receptor when expressed in myocyte cell lines. 24 An in vitro loss of receptor density after long-term exposure to isoproterenol has also been found. 12 In vivo, this genotype effect could lead to a decreased catecholamine effect, which, in turn, may decrease energy expenditure, for instance in adipose tissue, resulting in accumulation of fat. The latter is compatible with a weight increasing effect of the polymorphism. The Arg-allele of SNP 389 of the b1-adrenoceptor gene has been found to be associated with greater body weight and BMI. 25 Whether this could be explained by interactions with SNP 49, which was not examined, is unknown.
In conclusion, a functional Gly49-genotype of the b1-adrenoceptor gene, which occurs in a relatively large fraction of the population, is important for long-term changes in body weight and might promote development of adult-onset overweight.
